Lanreotide Autogel at Extended Dosing for Acromegaly Control

Acromegaly is a rare hormonal disorder caused by excessive production of growth hormone (GH) and insulin-like growth factor 1 (IGF-1), often due to a pituitary tumor. This leads to abnormal growth of hands, feet, and facial features, along with serious health complications like cardiovascular disease and diabetes. Somatostatin analogs like lanreotide Autogel (ATG) are a common treatment, typically administered every 4 weeks. However, extending these dosing intervals could improve patient convenience and reduce healthcare burden. This study aimed to evaluate the effectiveness of lanreotide Autogel 120 mg when administered at intervals longer than 4 weeks in real-world clinical practice.

The study successfully enrolled 115 actual subjects with acromegaly who were already on extended dosing regimens of lanreotide Autogel 120 mg. The primary outcome measured was the percentage of subjects achieving normal Insulin-like Growth Factor 1 (IGF-1) levels. While the study's summary indicates its purpose was to evaluate this effectiveness, the specific percentage of subjects who achieved normal IGF-1 levels under extended dosing intervals is not provided in the available abstract. However, the study confirmed the feasibility of observing a substantial cohort of 115 patients in a real-world setting, demonstrating the practical application of EDIs. This observational design allowed for the collection of data reflecting routine clinical practice, which is valuable for understanding treatment patterns outside of controlled clinical trials. The study's completion indicates that data was collected from 115 individuals to address the research question.